Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raptor Pharmaceuticals has signed a license agreement for the use of Mesd reagents for therapeutic treatment of cancer and osteoporosis with Washington University in St Louis.
Subscribe to our email newsletter
Mesd is a chaperone protein necessary for the proper folding of the signal transduction receptors LRP5 and LRP6. Mesd-based peptides may be useful in the therapeutic regulation of LRP5 and LRP6.
“Mesd significantly adds to our growing franchise in the drug targeting area. Similar to our RAP molecule, Mesd is a natural human receptor chaperone protein that has the potential to act as both a receptor targeting therapeutic, as well as a targeted delivery platform that could be used to deliver other drugs,” said Dr Christopher Starr, CEO of Raptor.
Raptor Pharmaceuticals is an early stage biotechnology research and development company which bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins.